Once-weekly 22μg subcutaneous IFN-β-1a in secondary progressive MS: A 3-year follow-up study on brain MRI measurements and serum MMP-9 levels

Acta Neurologica Scandinavica

Volumn 116, Issue 1, 2007, Pages 43-48

  Wu, X ^a   Kuusisto, H ^b   Dastidar, P ^b   Huhtala, H ^c   Nikkari, S T ^a   Ukkonen, M ^b   Hoyhtya M ^d   Elovaara, I ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d NONE   (Finland)

Author keywords

Brain atrophy; Interferon 1a; Magnetic resonance imaging; Matrix metalloproteinase 9; Secondary progressive multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GELATINASE B; PLACEBO; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; BRAIN; DRUG ADMINISTRATION; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT OUTCOME;

EID: 34250862285     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00780.x     Document Type: Article

References (35)

1. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999 122 : 191 7.
2. Ozenci V, Rinaldi L, Teleshova N et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun 1999 12 : 297 303.
3. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 1999 99 : 19 26.
4. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001 36 : 249 57.
5. Waubant E, Goodkin DE, Gee L et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999 53 : 1397 401.
6. Trojano M, Avolio C, Liuzzi GM et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999 53 : 1402 8.
7. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000 108 : 236 43.
8. Waubant E, Goodkin D, Bostrom A et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003 60 : 52 7.
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352 : 1498 504.
10. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999 46 : 197 206.
11. The Prisms Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 56 : 1628 36.
12. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999 53 : 679 86.
13. Durelli L, Oggero A, Verdun E et al. Interferon-beta dose and efficacy: the OPTIMS study. Neurol Sci 2001 22 : 201 3.
14. Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002 8 : 2 9.
15. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 359 : 1453 60.
16. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001 56 : 1496 504.
17. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352 : 1491 7.
18. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary- progressive MS. Neurology 2001 57 : 1969 75.
19. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 63 : 1788 95.
20. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001 56 : 1505 13.
21. Andersen O, Elovaara I, Farkkila M et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004 75 : 706 10.
22. Dastidar P, Heinonen T, Lehtimaki T et al. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci 1999 165 : 36 42.
23. Dastidar P, Heinonen T, Vahvelainen T, Elovaara I, Eskola H. Computerised volumetric analysis of lesions in multiple sclerosis using new semi-automatic segmentation software. Med Biol Eng Comput 1999 37 : 104 7.
24. Heinonen T, Dastidar P, Eskola H, Frey H, Ryymin P, Laasonen E. Applicability of semi-automatic segmentation for volumetric analysis of brain lesions. J Med Eng Technol 1998 22 : 173 8.
25. Kalela A, Koivu TA, Hoyhtya M et al. Association of serum MMP-9 with autoantibodies against oxidized LDL. Atherosclerosis 2002 160 : 161 5.
26. Verbeke G, Molenberghs G. Linear mixed models in practice: a Sas-oriented approach. Lect Notes Stat 1997 January : 15.
27. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 357 : 1576 82.
28. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343 : 898 904.
29. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 58 : S3 9.
30. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002 53 : 285 302.
31. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998 121 : 3 24.
32. Kappos L, Weinshenker B, Pozzilli C et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004 63 : 1779 87.
33. Avolio C, Giuliani F, Liuzzi GM et al. Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. Brain Res Bull 2003 61 : 357 64.
34. Chandler S, Miller KM, Clements JM et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997 72 : 155 61.
35. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002 58 : 1147 53.